EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. ABBV
7. DFTX
8. RGNX
9. GOOGL
10. LCO

Go back to EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
(NASDAQ: EYPT) Delayed: 13.57 -0.01 (0.07%)
Previous Close $13.58    52 Week High $ 
Open $13.62    52 Week Low $ 
Day High $13.92    P/E N/A 
Day Low $13.55    EPS $ 
Volume 158,315